Search Results 1111-1120 of 18013 for sickle cell
ROCHESTER, Minn. — Mayo Clinic researchers have uncovered how aging "zombie cells" trigger harmful inflammation that accelerates a severe and increasingly ...
ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
Science Saturday: Addressing the challenges of chimeric antigen receptor-T cell therapy featured image ... Preeclampsia linked to increased markers of brain cell ...
Durvalumab is FDA approved for treatment in lung cancers including non-small cell lung cancer and small cell lung cancer. Venetoclax is FDA approved for the ...
This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies displaying one of three different patterns of ...
Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies ...
D. September 17, 2024. More Mayo neuroscience: Brain cells 'crosstalk' and cancer growth; ...
H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of increasing immune response and protecting against breast cancer.
... cells collected from healthy subjects. We will identify innate immune cell populations that contribute to astrocyte reactivity and elucidate the mechanisms ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.